You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

Viatris Company Profile

✉ Email this page to a colleague

« Back to Dashboard

What is the competitive landscape for VIATRIS, and what generic and branded alternatives to VIATRIS drugs are available?

VIATRIS has seventeen approved drugs.

Summary for Viatris

US Patents:	0
Tradenames:	12
Ingredients:	10
NDAs:	17

Drugs and US Patents for Viatris

+ Get email alerts for changes to this table

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Viatris	DILANTIN-125	phenytoin	SUSPENSION;ORAL	008762-001	Approved Prior to Jan 1, 1982	AB	RX	Yes	Yes		⤷ Subscribe				⤷ Subscribe
Viatris	NEURONTIN	gabapentin	SOLUTION;ORAL	021129-001	Mar 2, 2000	AA	RX	Yes	Yes		⤷ Subscribe				⤷ Subscribe
Viatris	GEODON	ziprasidone hydrochloride	CAPSULE;ORAL	020825-002	Feb 5, 2001	AB	RX	Yes	No		⤷ Subscribe				⤷ Subscribe
Viatris	CARDURA	doxazosin mesylate	TABLET;ORAL	019668-003	Nov 2, 1990	AB	RX	Yes	No		⤷ Subscribe				⤷ Subscribe
Viatris	REVATIO	sildenafil citrate	SOLUTION;INTRAVENOUS	022473-001	Nov 18, 2009	AP	RX	Yes	Yes		⤷ Subscribe				⤷ Subscribe
Viatris	NORVASC	amlodipine besylate	TABLET;ORAL	019787-002	Jul 31, 1992	AB	RX	Yes	No		⤷ Subscribe				⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for Viatris

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Viatris	ZOLOFT	sertraline hydrochloride	TABLET;ORAL	019839-005	Mar 6, 1996	5,248,699*PED	⤷ Subscribe
Viatris	ZOLOFT	sertraline hydrochloride	TABLET;ORAL	019839-004	Dec 30, 1991	5,744,501	⤷ Subscribe
Viatris	NEURONTIN	gabapentin	SOLUTION;ORAL	021129-001	Mar 2, 2000	4,894,476*PED	⤷ Subscribe
Viatris	NEURONTIN	gabapentin	CAPSULE;ORAL	020235-002	Dec 30, 1993	5,084,479*PED	⤷ Subscribe
Viatris	ZOLOFT	sertraline hydrochloride	TABLET;ORAL	019839-003	Dec 30, 1991	5,248,699*PED	⤷ Subscribe
Viatris	REVATIO	sildenafil citrate	SOLUTION;INTRAVENOUS	022473-001	Nov 18, 2009	5,250,534*PED	⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Paragraph IV (Patent) Challenges for VIATRIS drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Capsules	20 mg, 40 mg, 60 mg and 80 mg	➤ Subscribe	2005-02-07
➤ Subscribe	Tablets	25 mg and 50 mg	➤ Subscribe	2004-11-19
➤ Subscribe	Sublingual Tablets	0.3 mg, 0.4 mg and 0.6 mg	➤ Subscribe	2005-10-19
➤ Subscribe	Tablets	150 mg and 200 mg	➤ Subscribe	2005-11-09
➤ Subscribe	Tablets	100 mg	➤ Subscribe	2004-10-25
➤ Subscribe	Sublingual Tablets	0.6 mg	➤ Subscribe	2011-12-29

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Viatris

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.